Caroline McCoach, PhD, MD

Thoracic oncologist

Dr. Caroline McCoach is a thoracic oncologist who specializes in treating adults with lung or other thoracic cancers. Her goal is to provide a personalized approach to treatment based on each patient's cancer type in combination with their individual goals.

McCoach's research focuses on integrating clinical findings with laboratory studies to improve patient care. Her work includes developing new drug therapies for lung cancers as well as investigating how cancer evolves to become resistant to targeted therapies. This research aims to help create new therapies that may delay or prevent cancer cell resistance to treatment.

McCoach earned a doctorate in biochemistry from Stanford University before earning her medical degree at the University of Colorado. She then completed her residency training in internal medicine at the University of California, Davis, where she was chief resident in her final year. She then completed a research fellowship at UC Davis, where she focused on the development of clinical trials for lung cancer therapies, before returning to the University of Colorado for a clinical fellowship in hematology and oncology, which concentrated on thoracic malignancies with gene mutations.

McCoach is a member of the American Society of Clinical Oncology and American Society of Hematology. She is an assistant professor at UCSF.

Clinics

Thoracic Surgery and Oncology
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone: (415) 885-3882
Fax: (415) 353-7151

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Academic Title

Assistant Professor

More about Caroline McCoach

Education

Stanford University, Ph.D., Biochemistry 2005
University of Colorado School of Medicine 2009

Residencies

UC Davis, Internal Medicine 2013

Fellowships

UC Davis, Medical Oncology 2014
University of Colorado School of Medicine, Hematology and Oncology 2017

Selected Research and Publications

  1. McCoach CE, Le A, Gowan K, Jones KL, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. Clin Cancer Res. 2018 Apr 10.
  2. McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le A, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res. 2018 Mar 29.
  3. McCoach CE, Bivona TG. The evolving understanding of immunoediting and the clinical impact of immune escape. J Thorac Dis. 2018 Mar; 10(3):1248-1252.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.